C4 Therapeutics Inc. (NASDAQ:CCCC)
|Dividend Rate (ttm)||0.0000|
|Trading Day||Nov 28|
|Day's Range||7.85 - 7.96|
|52 Week Range||4.84 - 38.05|
About C4 Therapeutics Inc.
C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity.
NewsNo news found.
C4 Therapeutics Inc. dividends
C4 Therapeutics Inc has a market cap or net worth of $389.70 million. The enterprise value is $0.
C4 Therapeutics Inc has 48.96 million shares outstanding.
The trailing PE ratio is 0.0000 and the forward PE ratio is -3.0854. C4 Therapeutics Inc's PEG ratio is 0.0000.
Stock Price Statistics
The stock price has decreased by -0.7537%. The beta is 2.0580, so C4 Therapeutics Inc's price volatility has been higher than the market average.
In the last 12 months, C4 Therapeutics Inc had revenue of $0 and earned $0 in profits. Earnings per share was $.